Diagnosis and initial management of Parkinson's disease

New England Journal of Medicine

Volumn 353, Issue 10, 2005, Pages 1021-1027

  Nutt, John G ^a,c   Wooten, G Frederick ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZATROPINE MESILATE; BROMOCRIPTINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE MESILATE; PETHIDINE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TRIHEXYPHENIDYL; UBIDECARENONE; ANTIPARKINSON AGENT;

ADULT; ANKLE EDEMA; ANOREXIA; ARM; ARM MOVEMENT; ARTICLE; BRAIN DEPTH STIMULATION; CASE REPORT; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COMPULSION; CONFUSION; CONSTIPATION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DYSKINESIA; ELBOW; FINGER; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HAND; HEART MUSCLE FIBROSIS; HUMAN; HYPOTENSION; INSOMNIA; LIMB; LIVEDO RETICULARIS; LUNG FIBROSIS; MALE; MEMORY DISORDER; MOTOR DYSFUNCTION; NAUSEA; NERVOUSNESS; NEUROPROTECTION; PARKINSON DISEASE; PHYSICAL EXAMINATION; PLEURAL FIBROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROPERITONEAL FIBROSIS; RIGIDITY; SIDE EFFECT; SOMNOLENCE; THALAMOTOMY; TREATMENT CONTRAINDICATION; TREMOR; URINE RETENTION; VALVULAR HEART DISEASE; VISUAL IMPAIRMENT; VOMITING; WALKING; WRIST; XEROSTOMIA; MIDDLE AGED; REVIEW;

ANTIPARKINSON AGENTS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGENTS; DOPAMINE AGONISTS; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 24344446871     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp043908     Document Type: Article

References (43)

1. de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995;45:2143-6.
2. Marras C, Tanner CM. Epidemiology of Parkinson's disease. In: Watts RL, Koller WC, eds. Movement disorders: neurologic principles & practice. 2nd ed. New York: McGraw-Hill, 2004:177-95.
3. U.S. interim projections by age, sex, race, and Hispanic origin. Washington, D.C.: U.S. Census Bureau, 2004. (Accessed August 11, 2005, at http://www.census.gov/ipc/www/usinterimproj/.)
4. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52:1214-20.
5. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 2004;75:637-9.
6. Lees AJ, Katzenschlager R, Head J, Ben Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 2001;57:1687-94.
7. Fall PA, Saleh A, Fredrickson M, Olsson JE, Granerus AK. Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord 2003;18:1312-6.
8. Healy DG, Abou-Sleiman PM, Wood NW. PINK, PANK, or PARK? A clinicians' guide to familial parkinsonism. Lancet Neurol 2004;3:652-62.
9. Payami H, Larsen K, Bernard S, Nutt J. Increased risk of Parkinson's disease in parents and siblings of patients. Ann Neurol 1994;36:659-61.
10. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
11. Gelb DJ, Oliver G, Gilman S. Diagnostic criteria for Parkinson's disease. Arch Neurol 1999;56:33-9.
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
13. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28:99-102.
14. Riley D, Lang AE, Blair RD, Birnbaum A, Reid B. Frozen shoulder and other shoulder disturbances in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989;52:63-6.
15. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415-23.
16. Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004;61:1224-9.
17. Clarke CE, Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69:590-4.
18. Hirsch MA, Toole T, Maitland CG, Rider RA. The effects of balance training and high-intensity resistance training on persons with idiopathic Parkinson's disease. Arch Phys Med Rehabil 2003;84:1109-17.
19. Ellis T, de Goede CJ, Feldman RG, Wolters EC, Kwakkel G, Wagenaar RC. Efficacy of a physical therapy program in patients with Parkinson's disease: a randomized controlled trial. Arch Phys Med Rehabil 2005;86:626-32.
20. Keyser DL, Rodnitzky RL. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med 1991;151:794-6.
21. Goetz CG, Koller WC, Poewe W, Rascol O, Sampaio C. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002;17:Suppl 4:S1-S166.
22. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameters: initial therapy of Parkinson's disease. Neurology 1993;43:1296-7.
23. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-7.
24. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-91.
25. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-53. [Erratum, Arch Neurol 2005;62:430.]
26. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 1999;53:1012-9.
27. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-8.
28. Agarwal P, Fahn S, Frucht SJ. Diagnosis and management of pergolide-induced fibrosis. Mov Disord 2004;19:699-704.
29. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280-6.
30. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-83.
31. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004;63:301-4.
32. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism trial. Ann Neurol 2002;51:604-12.
33. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-6.
34. Parkinson Study Group. Idem. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-61.
35. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
36. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50.
37. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003;60:1234-40.
38. Fahn S. Is levodopa toxic? Neurology 1996;47:Suppl 3:S184-S195.
39. Agid Y, Chase TN, Marsden CD. Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet 1998;351:851-2.
40. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508.
41. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19:997-1005.
42. Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996;93:14-20.
43. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-39.